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Background: The long-term influence of renal insufficiency (RI) on patient-related versus stent-related outcomes in patients undergoing 
percutaneous coronary intervention (PCI) has not been well characterized.
methods: Of 2,774 patients treated in the SORT OUT IV trial, baseline serum creatinie levels were available before PCI in 2,694 patients (97%). 
Estimated creatinine clearance (CrCl) was calculated by the formula: 186 × S-Cr-1.154 × age- 0.203 × 0.742 [if female]. A CrCl of ≤60 mL/
min was chosen to define RI. MACE was defined as a composite of cardiac death, myocardial infarction (MI), stent thrombosis, or target vessel 
revascularization (TVR) within 3 years. A safety outcome was assessed with specific focus on patient-related composite (all death, all MI, or any 
revascularization) and stent-related composite outcomes (cardiac death, target vessel MI, or target lesion revascularization (TLR)). The hazard ratio 
(HR) for MACE was estimated using a Cox regression model, controlling for potential confounders.
results: RI at baseline was present in 13% of patients. Patients with RI were older, more likely to be female and to have more comorbidity. At 
3-year MACE were higher among patients with versus without RI at baseline (with RI: 19.4% vs. without RI: 9.2%; HR=2.03 95% confidence interval 
(CI) (1.51- 2.72). The patient-related outcome: 30.0% patients with RI versus 16.9% patients without RI HR=1.56 95% CI (1.24-1.96),and the stent-
related outcome: 15.2% patients with RI versus 5.6% patients without RI HR=2.55 95% CI (1.79-3.62) were significantly higher in patients with RI. 
Risk of cardiac death HR=3.48, 95% CI (2.09-5.80), MI HR=1.40, 95% CI (0.77-2.56), TVR HR=1.58, 95% CI (1.07-2.35), and TLR HR=1.76, 95% CI 
(1.07-2.90) were higher in patients with RI compared to patients without RI. Risk of definite stent thrombosis did not differ between the two groups 
HR=1.41 95% CI (0.44-4.53). The clinical outcome did not differ significantly between everolimus-eluting stent and sirolimus-eluting stent treated 
patients with RI.
conclusions: In patients undergoing PCI, baseline RI is associated with increased risk of patient- and stent-related composite outcomes.
